Sign in Subscribe
Elsevier Science Inc.

Osteogenesis Imperfecta Study Reveals Substantial Clinical and Healthcare Burden

Strategic Insights

— 2 min read

A study published in the Journal of Bone has provided new insights into the clinical and healthcare burden associated with osteogenesis imperfecta (OI). Researchers from Sanofi conducted a real-world analysis using Optum's Clinformatics Data Mart Database to assess patients with OI in the United States. The study found that patients with OI experienced a higher frequency of healthcare resource utilization (HCRU) compared to controls, with significant differences in inpatient admissions, fracture rates, and costs.

Key Takeaways:

  • The study assessed 1367 patients with OI and 6835 non-OI controls using Optum's Clinformatics Data Mart Database.
  • Patients with OI had a higher frequency of HCRU, with 0.17 inpatient admissions per person-year (PPY) for those under 19 years, 0.20 PPY for those aged 20-54 years, and 0.32 PPY for those over 55 years.
  • Fracture rates were higher among patients with OI, with 47.5% of patients under 19 years experiencing fractures, compared to 33.4% of controls.
  • Costs per person-year for patients with OI were significantly higher, with $14,305 for those under 19 years, $17,119 for those aged 20-54 years, and $22,515 for those over 55 years.
  • The study concluded that these findings may inform the evaluation of disease-modifying therapies for OI.
  • Pranav Abraham, Sanofi, was the lead author of the study, which has been peer-reviewed and published in the Journal of Bone.

Statistics:

  • 1367 patients with OI were assessed in the study.
  • 6835 non-OI controls were matched with patients with OI.
  • 231 patients with OI were under 19 years (17.0%), 521 patients were aged 20-54 years (38.2%), and 522 patients were over 55 years (38.3%).
  • 47.5% of patients under 19 years experienced fractures.
  • 33.4% of controls experienced fractures.
  • Inpatient admissions for patients with OI were 0.17 PPY for those under 19 years, 0.20 PPY for those aged 20-54 years, and 0.32 PPY for those over 55 years.
  • Costs per person-year for patients with OI were $14,305 for those under 19 years, $17,119 for those aged 20-54 years, and $22,515 for those over 55 years.

Sources:

  • A real-world analysis of the clinical and healthcare burden associated with osteogenesis imperfecta. Bone, 2025;200:117572.
  • NewsRx. Researchers from Sanofi Report on Findings in Osteogenesis Imperfecta (A real-world analysis of the clinical and healthcare burden associated with osteogenesis imperfecta). Health & Medicine Week. September 26, 2025; p 176.

Read more